Oncternal Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€1.44M - Cost of goods sold
€16.05M - Gross profit
-€14.61M - SG&A expenses
€10.62M - R&D expenses
€22.22M - EBITDA
-€23.04M - D&A
€23.50M - EBIT
-€30.98M - Interest expenses
€6.89K - EBT
-€29.79M - Tax expenses
-€23.50M - Net income
-€29.79M
Cash flow statement
- Net deferred tax
€96.49K - Non-cash items
€1.94M - Changes in working capital
€748.69K - Operating cash flow
-€22.94M - Capex
€0.00 - Other investing cash flow
€9.67M - Net investing cash flow
€21.43M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€0.00 - Net financing cash flow
-€75.82K - Foreign exchange effects
€2.22M - Net change in cash
-€1.59M - Cash at end of period
€11.27M - Free cash flow
-€22.94M
Balance sheet
- Cash and cash equivalents
€11.27M - Cash and short-term investments
€12.56M - Total receivables
€296.37K - Inventory
€0.00 - Other current assets
€452.31K - Total current assets
€13.31M - Property, plant & equipment
€132.68K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€132.68K - Total assets
€13.44M - Accounts payable
€1.03M - Short-term debt
€164.56K - Other current liabilities
€4.36M - Total current liabilities
€5.56M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€5.56M - Common stock
€2.58K - Retained earnings
-€192.29M - Other equity
€861.55 - Total equity
€7.88M - Total liabilities and shareholders' equity
€13.44M
Company information
- Market capitalization
€1.33M - Employees
27 - Enterprise Value
-€11.33M
Company ratios
- Gross margin
-
-1,017.6% Much worse than peer group: -715.8% - EBITDA margin
-
-1,603.9% Much better than peer group: -5,434.8% - EBIT margin
-
-2,157.1% Much better than peer group: -6,134.5% - EBT margin
-
-2,074.1% Much better than peer group: -4,506.7% - Net margin
-
-2,074.1% Much better than peer group: -6,403.6% - ROE
-
-378.0% Much worse than peer group: -114.1% - ROA
-
-221.6% Much worse than peer group: -123.5% - Asset turnover
-
10.7% Much better than peer group: -760.0% - FCF margin
-
-1,597.6% Much better than peer group: -4,685.6% - FCF yield
-1,726.0% - Efficiency ratio
1,703.9% - Net sales per employee
-
€53.19K - Net income per employee
-
-€1.10M